@article{nguessanComparativeTheranosticEfficacy2025,
	title = {Comparative theranostic efficacy of {177Lu}- and {161Tb}-labeled {A1K2} {SdAb} in mesothelin-positive tumors},
	issn = {1619-7089},
	url = {https://doi.org/10.1007/s00259-025-07723-z},
	doi = {10.1007/s00259-025-07723-z},
	abstract = {Mesothelin (MSLN), a 40 kDa glycoprotein normally confined to mesothelial cells, is overexpressed in several malignancies, including triple-negative breast cancer (TNBC). The anti-mesothelin single-domain antibody (sdAb, or “nanobody®”) DOTA-A1K2, previously validated for positron emission tomography (PET) imaging using site-specific 68Ga radiolabeling, may also serve as a radio-theranostic agent when labeled with 177Lu. Moreover, 161Tb has recently been proposed as an alternative to 177Lu that might provide additional efficacy due to the emission of Auger electrons. The aim of this study was to evaluate in vitro and in vivo the therapeutic effect of [177Lu]Lu-DOTA-A1K2 and [161Tb]Tb-DOTA-A1K2.},
	language = {en},
	urldate = {2026-02-23},
	journal = {European Journal of Nuclear Medicine and Molecular Imaging},
	author = {N’Guessan, Émilien and Raes, Florian and Ahmadi, Mitra and Bacot, Sandrine and Dumas, Laurent and Leenhardt, Julien and du Moulinet d’Hardemare, Amaury and Debiossat, Marlène and André, Clémence and Boutonnat, Jean and Durivault, Jérôme and Montemagno, Christopher and Lenormand, Jean-Luc and Djaïleb, Loïc and Köster, Ulli and Van de Voorde, Michiel and Ramaekers, Stijn and Verguts, Ken and Ghezzi, Catherine and Perret, Pascale and Lombardi, Charlotte and Broisat, Alexis},
	month = dec,
	year = {2025},
	keywords = {Lutetium-177, Mesothelin, Radio-ligand therapy, SdAb, Terbium-161, Triple negative breast cancer, user-project},
}